Researchers Developed Dual Inhibitor for Malaria
A new drug treatment cleared liver-stage malaria infections and induced long-term immunity in preclinical mouse models.
Updated on Sept. 24, 2026 in Diseases — General
Live Poll
Should medical research prioritize developing long-term preventative vaccines over creating new treatment drugs?
Scientists have created a dual inhibitor drug that targets two parasite enzymes to treat and prevent malaria. The treatment successfully cleared liver-stage infections in mice and triggered a robust immune response that provided protection against re-infection.
Why it matters
By targeting two parasite enzymes simultaneously, this approach aims to significantly reduce the risk of malaria parasites developing drug resistance. This strategy could offer a new pathway to combat a disease that currently causes approximately 600,000 deaths every year.
Researchers identified plasmepsin IX and X as the target enzymes for the compounds WM382 and MK-7602. Treated mice exhibited a sustained immune response, remaining protected against re-infection for six months in initial tests.
The players
Walter and Eliza Hall Institute of Medical Research
This organization served as a primary collaborator on the drug development project.
Merck
This pharmaceutical company partnered with researchers to develop the dual inhibitor compounds.
The details
The dual inhibitors WM382 and its optimized successor MK-7602 work by creating chemo-attenuated liver merozoites that trigger CD8 T cell and antibody responses. This process limited parasite progression in humanized mice, effectively training the immune system to recognize and defend against the parasite.
Timeline
Collaboration between Merck and WEHI began a decade ago.
Treated mice demonstrated immunity against re-infection six months later.
Preclinical models showed the duration of induced immunity reached two years.
The Big Picture
This development represents a departure from traditional single-target therapies, aligning with broader scientific efforts to overcome the R21/Matrix-M malaria vaccine limitations. It seeks to provide a durable pharmaceutical alternative that addresses the high global mortality rate of malaria.
The potential transition to a long-acting injectable treatment could eventually simplify malaria prevention protocols for individuals in high-risk regions. Future clinical availability would change how healthcare providers approach both the treatment of active infections and long-term immunity.
The takeaway
The successful induction of long-term immunity in preclinical models highlights the power of multi-target drug inhibition in infectious disease research. Future developments will focus on human safety and the scalability of long-acting delivery methods for global populations.
Further reading
For more information on medical advancements, visit the Diseases — General section.
Source note: This article includes information reported by The Scientist.
Live Poll
Should medical research prioritize developing long-term preventative vaccines over creating new treatment drugs?
